Top 200 Drugs for 2010 by Sales
2010
| Rank | Drug | Current Manufacturer | Total Sales ($000) | % change 2009 |
| 1 (1) | Nexium | AstraZeneca Pharmaceuticals | 5,276,153 | 4.9% |
| 2 (1) | Lipitor | Pfizer Inc | 5,272,576 | -2.3% |
| 3 | Plavix | Bristol-Myers Squibb Company | 4,675,483 | 10.2% |
| 4 | Advair Diskus | GlaxoSmithKline | 3,655,206 | -1.0% |
| 5 (3) | OxyContin | Purdue Pharma LP | 3,554,751 | 13.1% |
| 6 | Abilify | Bristol-Myers Squibb Company | 3,514,265 | 12.7% |
| 7 | Singulair | Merck & Co., Inc. | 3,324,909 | 8.9% |
| 8 (3) | Seroquel | AstraZeneca Pharmaceuticals | 3,222,055 | 2.4% |
| 9 (5) | Crestor | AstraZeneca Pharmaceuticals | 2,922,687 | 27.0% |
| 10 (1) | Cymbalta | Eli Lilly and Company | 2,638,536 | 7.6% |
| 11 (2) | Actos | Takeda Pharmaceuticals North America, Inc | 2,631,930 | 4.2% |
| 12 (1) | Lexapro | Forest Pharmaceuticals, Inc | 2,483,391 | 4.6% |
| 13 (2) | Zyprexa | Eli Lilly and Company | 2,036,092 | 7.7% |
| 14 (9) | Spiriva | Boehringer Ingelheim Pharmaceuticals, Inc | 1,593,593 | 19.3% |
| 15 (3) | Lantus | Sanofi-Aventis | 1,525,697 | 0.3% |
| 16 (6) | Aricept | Eisai Corporation | 1,522,517 | 13.3% |
| 17 (2) | Lyrica | Pfizer Inc | 1,478,158 | -0.1% |
| 18 (6) | Diovan | Novartis Corporation | 1,443,539 | 7.0% |
| 19 (7) | Effexor XR | Wyeth | 1,431,042 | -40.1% |
| 20 (7) | Concerta | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | 1,407,962 | 16.9% |
| 21 | Levaquin | Janssen Pharmaceuticals, Inc | 1,355,350 | -0.6% |
| 22 (2) | Celebrex | Pfizer Inc | 1,349,833 | -6.9% |
| 23 (2) | Diovan HCT | Novartis Corporation | 1,314,507 | 3.7% |
| 24 (4) | Januvia | Merck & Co., Inc. | 1,294,408 | 13.0% |
| 25 (16) | Suboxone | Reckitt Benckiser Pharmaceuticals Inc. | 1,164,872 | 26.6% |
| 26 (14) | NovoLog | Novo Nordisk Inc. | 1,101,447 | 20.6% |
| 27 (9) | Viagra | Pfizer Inc | 1,028,769 | 5.5% |
| 28 (4) | Atripla | Gilead Sciences, Inc. | 1,028,753 | -6.5% |
| 29 (3) | Tricor | Abbott Laboratories | 1,015,682 | -17.2% |
| 30 (13) | Provigil | Cephalon, Inc. | 999,975 | 6.7% |
| 31 (2) | Zetia | Schering-Plough | 985,823 | -4.3% |
| 32 (12) | Geodon oral | Pfizer Inc | 959,057 | 8.7% |
| 33 (4) | Vytorin | Merck & Co., Inc. | 953,625 | -16.3% |
| 34 (1) | Ambien CR | Sanofi-Aventis | 951,108 | -2.5% |
| 35 (11) | Lunesta | Sepracor Inc. (renamed Sunovion Pharmaceuticals Inc) | 948,621 | 17.6% |
| 36 (2) | Lidoderm | Endo Pharmaceuticals | 934,418 | -1.1% |
| 37 (22) | Lantus SoloSTAR | Sanofi-Aventis | 933,589 | 50.5% |
| 38 (15) | Vyvanse | Shire US Inc | 931,421 | 40.9% |
| 39 (5) | Aciphex | Eisai Corporation | 915,796 | -8.8% |
| 40 (2) | Nasonex | Schering-Plough | 886,446 | -1.9% |
| 41 (10) | Lovenox | Sanofi-Aventis | 867,240 | -20.4% |
| 42 (12) | Adderall XR | Shire US Inc | 837,448 | -27.0% |
| 43 (4) | ProAir HFA | Teva Pharmaceuticals | 818,903 | -12.6% |
| 44 (1) | Truvada | Gilead Sciences, Inc. | 813,944 | -8.5% |
| 45 (3) | Niaspan | Abbott Laboratories | 793,882 | 11.0% |
| 46 (1) | Humalog | Eli Lilly and Company | 783,294 | 3.2% |
| 47 (8) | Cialis | Eli Lilly and Company | 756,576 | 15.9% |
| 48 (4) | Namenda | Forest Pharmaceuticals, Inc | 744,296 | 10.9% |
| 49 (27) | Symbicort | AstraZeneca Pharmaceuticals | 707,468 | 47.4% |
| 50 (8) | Flovent HFA | GlaxoSmithKline | 704,631 | 13.2% |
| 51 (52) | Seroquel XR | AstraZeneca Pharmaceuticals | 695,560 | 92.1% |
| 52 (8) | Combivent | Boehringer Ingelheim Pharmaceuticals, Inc | 693,068 | 14.3% |
| 53 () | Lovaza | GlaxoSmithKline | 682,384 | 15.5% |
| 54 (24) | Solodyn | Medicis Pharmaceutical Corporation | 673,427 | 40.7% |
